Drug Profile
CGS 32359
Alternative Names: C5aRADLatest Information Update: 20 Aug 2002
Price :
$50
*
At a glance
- Originator Novartis
- Class Anti-ischaemics
- Mechanism of Action Complement C5a inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Reperfusion injury